Advantages of using ACQUITY PREMIER System and Columns with MaxPeak HPS Technology for Bioanalysis of Gefitinib – an EGFR Inhibitor

Library Number:
APNT135080190
Part Number:
720007122EN
Author(s):
Nikunj Tanna, Robert S. Plumb
Source:
Waters
Content Type:
Application Notes
Content Subtype:
Technical Notes
Related Products:
 
 
 
 
 
 
 
 

In this application brief, we investigate the effect of these novel hybrid barrier surface technologies on metal insensitive compounds. Gefitinib (Iressa) was chosen as a candidate molecule for this study. Gefitinib is an epidermal growth factor receptor (EGFR) inhibitor and is indicated in non-small cell lung cancer (NSCLC) and certain breast cancer patients. There are no known reports of metal sensitivity exhibited by Gefitinib, however previous reported bioanalytical methods for this compound have all employed buffers in the mobile phase to improve chromatographic peak shape. Here, we show that using ACQUITY PREMIER and MaxPeak HPS Columns improves the robustness and reproducibility for bioanalysis of gefitinib.


Title Format File Size
Download PDF PDF 235.85kB